Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder with progressive damage to brain cells. It is the leading cause of dementia worldwide that is characterized by impairment of memory and eventually by reasoning and perception disturbances. No curative treatment for dementia is currently available. With the progress of RNA sequencing and transcriptome analysis, the discovery of non-protein coding RNAs expands our knowledge about the genome. Long non-coding RNAs (lncRNAs) which are involved in a wide variety of biological processes as regulatory molecule, have been the focus of much recent research. In this review, we focus on the emerging roles of these lncRNAs in the pathology of Alzheimer’s disease. Their expressions are brain-specific and dysregulated in the patient and animal model. Here, we will summarize the pathological features influenced by lncRNAs and therefore provide an lncRNA point-of-view on AD. This should stimulate new research directions and therapeutic options considering lncRNAs as novel prognostic markers and therapeutic targets.
Keywords: Alzheimer’s disease, Drug discovery, Long non-coding RNA, Regulator molecular.
Current Topics in Medicinal Chemistry
Title:Long non-coding RNAs in Alzheimer’s disease
Volume: 16 Issue: 5
Author(s): Zijian Zhang
Affiliation:
Keywords: Alzheimer’s disease, Drug discovery, Long non-coding RNA, Regulator molecular.
Abstract: Alzheimer’s disease (AD) is a neurodegenerative disorder with progressive damage to brain cells. It is the leading cause of dementia worldwide that is characterized by impairment of memory and eventually by reasoning and perception disturbances. No curative treatment for dementia is currently available. With the progress of RNA sequencing and transcriptome analysis, the discovery of non-protein coding RNAs expands our knowledge about the genome. Long non-coding RNAs (lncRNAs) which are involved in a wide variety of biological processes as regulatory molecule, have been the focus of much recent research. In this review, we focus on the emerging roles of these lncRNAs in the pathology of Alzheimer’s disease. Their expressions are brain-specific and dysregulated in the patient and animal model. Here, we will summarize the pathological features influenced by lncRNAs and therefore provide an lncRNA point-of-view on AD. This should stimulate new research directions and therapeutic options considering lncRNAs as novel prognostic markers and therapeutic targets.
Export Options
About this article
Cite this article as:
Zhang Zijian, Long non-coding RNAs in Alzheimer’s disease , Current Topics in Medicinal Chemistry 2016; 16 (5) . https://dx.doi.org/10.2174/1568026615666150813142956
DOI https://dx.doi.org/10.2174/1568026615666150813142956 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Radiosensitizing Potential of Epigenetic Anticancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Current Pharmaceutical Design New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets Targeted Toxins for Glioblastoma Multiforme: Pre-Clinical Studies and Clinical Implementation
Anti-Cancer Agents in Medicinal Chemistry 7-aa Peptide Mimic from HVR1 of HCV Protects Hepatic Injury in Rats by Reduced Expression of Key Pro-Inflammatory Factors
Inflammation & Allergy - Drug Targets (Discontinued) Potential Benefits of Glitazones for Cancer and Vascular Disease
Current Drug Therapy Targeting Striatal Metabotropic Glutamate Receptor Type 5 in Parkinson’s Disease: Bridging Molecular Studies and Clinical Trials
CNS & Neurological Disorders - Drug Targets Tyrosol and Hydroxytyrosol Two Main Components of Olive Oil, Protect N2a Cells Against Amyloid-β-Induced Toxicity. Involvement of the NF-κB Signaling
Current Alzheimer Research Associative Learning, the Hippocampus, and Nicotine Addiction
Current Drug Abuse Reviews Targeting the Tumor Proteasome as a Mechanism to Control the Synthesis and Bioactivity of Matrix Macromolecules
Current Molecular Medicine Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Nutritional and Medical Applications of Spirulina Microalgae
Mini-Reviews in Medicinal Chemistry Treatment of CNS Malignancies with a Recombinant Oncolytic Poliovirus
Drug Design Reviews - Online (Discontinued) Cilostazol as a Unique Antithrombotic Agent
Current Pharmaceutical Design Targeting Calcium Channels to Block Tumor Vascularization
Recent Patents on Anti-Cancer Drug Discovery Mast Cells: Target and Source of Neuropeptides
Current Pharmaceutical Design Promising Targets in Anti-cancer Drug Development: Recent Updates
Current Medicinal Chemistry ROCK in CNS: Different Roles of Isoforms and Therapeutic Target for Neurodegenerative Disorders
Current Drug Targets The Pharmacokinetics and Toxicology of Aluminum in the Brain
Current Inorganic Chemistry (Discontinued) Therapeutic Targeting of the Endoplasmic Reticulum in Alzheimers Disease
Current Alzheimer Research